View ValuationPlexBio 将来の成長Future 基準チェック /06現在、 PlexBioの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Medical Equipment 収益成長19.5%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesReported Earnings • Apr 16Full year 2025 earnings released: NT$0.60 loss per share (vs NT$0.59 loss in FY 2024)Full year 2025 results: NT$0.60 loss per share (further deteriorated from NT$0.59 loss in FY 2024). Revenue: NT$127.1m (flat on FY 2024). Net loss: NT$62.5m (loss widened 1.4% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 7% per year whereas the company’s share price has fallen by 12% per year.お知らせ • Mar 27PlexBio Co., Ltd., Annual General Meeting, Jun 29, 2026PlexBio Co., Ltd., Annual General Meeting, Jun 29, 2026. Location: 5 floor no,285, sec.4 chung hsiao e. rd., da-an district, taipei city TaiwanNew Risk • Mar 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Revenue is less than US$5m (NT$153m revenue, or US$4.9m). Market cap is less than US$100m (NT$848.9m market cap, or US$27.1m).New Risk • Jan 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.5% average weekly change). Revenue is less than US$5m (NT$153m revenue, or US$4.8m). Market cap is less than US$100m (NT$959.8m market cap, or US$30.3m).New Risk • Jul 15New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.4% average weekly change). Revenue is less than US$5m (NT$128m revenue, or US$4.4m). Market cap is less than US$100m (NT$1.04b market cap, or US$35.5m).お知らせ • Mar 25PlexBio Co., Ltd., Annual General Meeting, Jun 19, 2025PlexBio Co., Ltd., Annual General Meeting, Jun 19, 2025. Location: 5 floor no,285, sec.4 chung hsiao e. rd., da-an district, taipei city TaiwanNew Risk • Mar 03New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (6.8% average weekly change). Revenue is less than US$5m (NT$104m revenue, or US$3.1m). Market cap is less than US$100m (NT$1.17b market cap, or US$35.6m).New Risk • Dec 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.1% average weekly change). Revenue is less than US$5m (NT$104m revenue, or US$3.2m). Market cap is less than US$100m (NT$1.22b market cap, or US$37.4m).Reported Earnings • Apr 27Full year 2023 earnings released: NT$0.56 loss per share (vs NT$0.51 loss in FY 2022)Full year 2023 results: NT$0.56 loss per share (further deteriorated from NT$0.51 loss in FY 2022). Revenue: NT$167.2m (down 13% from FY 2022). Net loss: NT$58.5m (loss widened 10% from FY 2022). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.お知らせ • Mar 30PlexBio Co., Ltd., Annual General Meeting, Jun 18, 2024PlexBio Co., Ltd., Annual General Meeting, Jun 18, 2024.New Risk • Mar 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (NT$1.40b market cap, or US$44.4m).New Risk • Feb 13New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 5.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (5.4% average weekly change). Market cap is less than US$100m (NT$1.43b market cap, or US$45.4m).Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Representative Director Rimiru Hayashida was the last director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Aug 19First half 2022 earnings released: EPS: NT$0 (vs NT$0.57 loss in 1H 2021)First half 2022 results: EPS: NT$0 (up from NT$0.57 loss in 1H 2021). Revenue: NT$108.1m (up 55% from 1H 2021). Net loss: NT$30.9m (loss narrowed 48% from 1H 2021).Reported Earnings • May 02Full year 2021 earnings released: NT$1.27 loss per share (vs NT$1.37 loss in FY 2020)Full year 2021 results: NT$1.27 loss per share (up from NT$1.37 loss in FY 2020). Revenue: NT$124.9m (up 23% from FY 2020). Net loss: NT$131.6m (loss narrowed 6.7% from FY 2020). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Representative Director Rimiru Hayashida was the last director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Apr 04PlexBio Co., Ltd., Annual General Meeting, Jun 23, 2022PlexBio Co., Ltd., Annual General Meeting, Jun 23, 2022.Reported Earnings • Apr 28Full year 2020 earnings released: NT$1.37 loss per share (vs NT$2.32 loss in FY 2019)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: NT$101.3m (up 42% from FY 2019). Net loss: NT$141.1m (loss narrowed 24% from FY 2019). Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.Is New 90 Day High Low • Feb 18New 90-day low: NT$20.10The company is down 22% from its price of NT$25.70 on 20 November 2020. The Taiwanese market is up 18% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is down 10.0% over the same period.分析記事 • Feb 16PlexBio (GTSM:6572) Shareholders Have Enjoyed A 11% Share Price GainIt hasn't been the best quarter for PlexBio Co., Ltd. ( GTSM:6572 ) shareholders, since the share price has fallen 20...分析記事 • Dec 22We Think PlexBio (GTSM:6572) Can Afford To Drive Business GrowthWe can readily understand why investors are attracted to unprofitable companies. For example, although...Is New 90 Day High Low • Dec 10New 90-day low: NT$20.45The company is down 51% from its price of NT$41.50 on 11 September 2020. The Taiwanese market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is down 1.0% over the same period.Is New 90 Day High Low • Oct 29New 90-day low: NT$25.40The company is down 61% from its price of NT$65.60 on 31 July 2020. The Taiwanese market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is down 9.0% over the same period.Is New 90 Day High Low • Oct 13New 90-day low: NT$28.55The company is down 52% from its price of NT$59.90 on 15 July 2020. The Taiwanese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is down 16% over the same period.Is New 90 Day High Low • Sep 24New 90-day low: NT$37.45The company is down 46% from its price of NT$69.80 on 24 June 2020. The Taiwanese market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is down 14% over the same period. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、PlexBio は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測TPEX:6572 - アナリストの将来予測と過去の財務データ ( )TWD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/2025127-62-80-79N/A9/30/2025140-63-121-120N/A6/30/2025153-65-163-160N/A3/31/2025141-63-86-83N/A12/31/2024128-62-9-5N/A9/30/2024116-653033N/A6/30/2024104-696971N/A3/31/2024135-641821N/A12/31/2023167-59-32-29N/A9/30/2023174-56-32-29N/A6/30/2023180-53-32-29N/A3/31/2023186-53-53-50N/A12/31/2022191-53-73-71N/A9/30/2022177-78-63-59N/A6/30/2022163-103-53-47N/A3/31/2022144-118-74-66N/A12/31/2021125-132-96-84N/A9/30/2021140-117-143-132N/A6/30/2021156-102-190-180N/A3/31/2021129-122-154-146N/A12/31/2020101-141-117-111N/A9/30/202084-168-117-108N/A6/30/202066-195-116-106N/A3/31/202069-190-99-88N/A12/31/201971-185-83-71N/A9/30/201977-197N/A-80N/A6/30/201983-209N/A-90N/A3/31/201982-218N/A-144N/A12/31/201881-226N/A-197N/A9/30/201853-223N/A-197N/A6/30/201824-221N/A-197N/A3/31/201825-221N/A-199N/A12/31/201727-221N/A-200N/A9/30/201732-216N/A-201N/A6/30/201738-211N/A-201N/A3/31/201727-205N/A-189N/A12/31/201617-200N/A-178N/A9/30/201611-220N/A-167N/A6/30/20165-239N/A-156N/A3/31/20165-227N/A-146N/A12/31/20156-215N/A-136N/A9/30/20156-177N/A-126N/A6/30/20155-139N/A-117N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 6572の予測収益成長が 貯蓄率 ( 1.3% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 6572の収益がTW市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 6572の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 6572の収益がTW市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 6572の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 6572の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/18 13:13終値2026/06/18 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋PlexBio Co., Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Reported Earnings • Apr 16Full year 2025 earnings released: NT$0.60 loss per share (vs NT$0.59 loss in FY 2024)Full year 2025 results: NT$0.60 loss per share (further deteriorated from NT$0.59 loss in FY 2024). Revenue: NT$127.1m (flat on FY 2024). Net loss: NT$62.5m (loss widened 1.4% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 7% per year whereas the company’s share price has fallen by 12% per year.
お知らせ • Mar 27PlexBio Co., Ltd., Annual General Meeting, Jun 29, 2026PlexBio Co., Ltd., Annual General Meeting, Jun 29, 2026. Location: 5 floor no,285, sec.4 chung hsiao e. rd., da-an district, taipei city Taiwan
New Risk • Mar 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Revenue is less than US$5m (NT$153m revenue, or US$4.9m). Market cap is less than US$100m (NT$848.9m market cap, or US$27.1m).
New Risk • Jan 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.5% average weekly change). Revenue is less than US$5m (NT$153m revenue, or US$4.8m). Market cap is less than US$100m (NT$959.8m market cap, or US$30.3m).
New Risk • Jul 15New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.4% average weekly change). Revenue is less than US$5m (NT$128m revenue, or US$4.4m). Market cap is less than US$100m (NT$1.04b market cap, or US$35.5m).
お知らせ • Mar 25PlexBio Co., Ltd., Annual General Meeting, Jun 19, 2025PlexBio Co., Ltd., Annual General Meeting, Jun 19, 2025. Location: 5 floor no,285, sec.4 chung hsiao e. rd., da-an district, taipei city Taiwan
New Risk • Mar 03New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (6.8% average weekly change). Revenue is less than US$5m (NT$104m revenue, or US$3.1m). Market cap is less than US$100m (NT$1.17b market cap, or US$35.6m).
New Risk • Dec 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.1% average weekly change). Revenue is less than US$5m (NT$104m revenue, or US$3.2m). Market cap is less than US$100m (NT$1.22b market cap, or US$37.4m).
Reported Earnings • Apr 27Full year 2023 earnings released: NT$0.56 loss per share (vs NT$0.51 loss in FY 2022)Full year 2023 results: NT$0.56 loss per share (further deteriorated from NT$0.51 loss in FY 2022). Revenue: NT$167.2m (down 13% from FY 2022). Net loss: NT$58.5m (loss widened 10% from FY 2022). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.
お知らせ • Mar 30PlexBio Co., Ltd., Annual General Meeting, Jun 18, 2024PlexBio Co., Ltd., Annual General Meeting, Jun 18, 2024.
New Risk • Mar 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (NT$1.40b market cap, or US$44.4m).
New Risk • Feb 13New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 5.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (5.4% average weekly change). Market cap is less than US$100m (NT$1.43b market cap, or US$45.4m).
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Representative Director Rimiru Hayashida was the last director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Aug 19First half 2022 earnings released: EPS: NT$0 (vs NT$0.57 loss in 1H 2021)First half 2022 results: EPS: NT$0 (up from NT$0.57 loss in 1H 2021). Revenue: NT$108.1m (up 55% from 1H 2021). Net loss: NT$30.9m (loss narrowed 48% from 1H 2021).
Reported Earnings • May 02Full year 2021 earnings released: NT$1.27 loss per share (vs NT$1.37 loss in FY 2020)Full year 2021 results: NT$1.27 loss per share (up from NT$1.37 loss in FY 2020). Revenue: NT$124.9m (up 23% from FY 2020). Net loss: NT$131.6m (loss narrowed 6.7% from FY 2020). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.
Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Representative Director Rimiru Hayashida was the last director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 04PlexBio Co., Ltd., Annual General Meeting, Jun 23, 2022PlexBio Co., Ltd., Annual General Meeting, Jun 23, 2022.
Reported Earnings • Apr 28Full year 2020 earnings released: NT$1.37 loss per share (vs NT$2.32 loss in FY 2019)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: NT$101.3m (up 42% from FY 2019). Net loss: NT$141.1m (loss narrowed 24% from FY 2019). Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.
Is New 90 Day High Low • Feb 18New 90-day low: NT$20.10The company is down 22% from its price of NT$25.70 on 20 November 2020. The Taiwanese market is up 18% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is down 10.0% over the same period.
分析記事 • Feb 16PlexBio (GTSM:6572) Shareholders Have Enjoyed A 11% Share Price GainIt hasn't been the best quarter for PlexBio Co., Ltd. ( GTSM:6572 ) shareholders, since the share price has fallen 20...
分析記事 • Dec 22We Think PlexBio (GTSM:6572) Can Afford To Drive Business GrowthWe can readily understand why investors are attracted to unprofitable companies. For example, although...
Is New 90 Day High Low • Dec 10New 90-day low: NT$20.45The company is down 51% from its price of NT$41.50 on 11 September 2020. The Taiwanese market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is down 1.0% over the same period.
Is New 90 Day High Low • Oct 29New 90-day low: NT$25.40The company is down 61% from its price of NT$65.60 on 31 July 2020. The Taiwanese market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is down 9.0% over the same period.
Is New 90 Day High Low • Oct 13New 90-day low: NT$28.55The company is down 52% from its price of NT$59.90 on 15 July 2020. The Taiwanese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is down 16% over the same period.
Is New 90 Day High Low • Sep 24New 90-day low: NT$37.45The company is down 46% from its price of NT$69.80 on 24 June 2020. The Taiwanese market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is down 14% over the same period.